Evidence map›Paper›PMID 35945955›Full record

ArticleInfectious Disease Modelling2022

Predictive model of risk factors of High Flow Nasal Cannula using machine learning in COVID-19.

Nobuaki Matsunaga, Keisuke Kamata, Yusuke Asai, Shinya Tsuzuki, Yasuaki Sakamoto, Shinpei Ijichi, Takayuki Akiyama, Jiefu Yu, Gen Yamada, Mari Terada and 5 more

Open access · goldAbstract read
In one paragraph

Article in Infectious Disease Modelling, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 1 institution in 1 country.

Nobuaki MatsunagaAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Keisuke KamataDataRobot Inc., Tokyo, Japan.
Yusuke AsaiAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Shinya TsuzukiAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Yasuaki SakamotoDataRobot Inc., Tokyo, Japan.
Shinpei IjichiDataRobot Inc., Tokyo, Japan.
Takayuki AkiyamaAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Jiefu YuAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Gen YamadaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Mari TeradaDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Setsuko SuzukiDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kumiko SuzukiAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Sho SaitoDisease Control and Prevention Center, National Center for Global Health and Medicine, Tokyo, Japan.
Kayoko HayakawaAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
Norio OhmagariAMR Clinical Reference Center, National Center for Global Health and Medicine, Tokyo, Japan.
National Center for Global Health and Medicine · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

With the rapid increase in the number of COVID-19 patients in Japan, the number of patients receiving oxygen at home has also increased rapidly, and some of these patients have died. An efficient approach to identify high-risk patients with slowly progressing and rapidly worsening COVID-19, and to avoid missing the timing of therapeutic intervention will improve patient prognosis and prevent medical complications. Patients admitted to medical institutions in Japan from November 14, 2020 to April 11, 2021 and registered in the COVID-19 Registry Japan were included. Risk factors for patients with High Flow Nasal Cannula invasive respiratory management or higher were comprehensively explored using machine learning. Age-specific cohorts were created, and severity prediction was performed for the patient surge period. We were able to obtain a model that was able to predict severe disease with a sensitivity of 57% when the specificity was set at 90% for those aged 40-59 years, and with a specificity of 50% and 43% when the sensitivity was set at 90% for those aged 60-79 years and 80 years and older, respectively. We were able to identify lactate dehydrogenase level (LDH) as an important factor in predicting the severity of illness in all age groups. Using machine learning, we were able to identify risk factors with high accuracy, and predict the severity of the disease. We plan to develop a tool that will be useful in determining the indications for hospitalisation for patients undergoing home care and early hospitalisation.

Indexed as

COVID-19JapanMachine learningRisk predictionSeverity

Identifiers

PMID35945955
PMCPMC9352414
OpenAlexW4289833770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.